Cas No.: | 865783-95-5 |
Synonyms: | ON-013100,ON 013100,ON013100 |
SMILES: | OC1=CC(CS(=O)(/C=C/C2=C(OC)C=C(OC)C=C2OC)=O)=CC=C1OC |
Formula: | C19H22O7S |
M.Wt: | 394.44 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression. |
Target: | Cdk4/cyclin D1 |
In Vitro: | ON-013100 induces apoptosis, and has activity against most human cancer cell lines in vitro. ON013100 significantly alters the cell cycle profile, dramatically increasing the number of cells in G2/M phase. Treatment of the cells with even 0.1 μM of ON013100 results in an arrest of the G2/M phase of the cell cycle[2]. ON 013100 inhibits the proliferation of MCL (JEKO-1 and MINO), breast (MCF7 and MDA-MB-231), gastric (AGS), and esophageal (OE19, OE33, and FLO-1) cancer cell lines at a nanomolar concentration (ON 013100 GI50=6.7-11.2 nM) [3]. |
References: | [1]. Cho SY, et al. Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MS. J Pharm Biomed Anal. 2013 Mar 5;75:138-44. [2]. Park IW, et al. Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. Oncogene. 2007 Aug 16;26(38):5635-42. [3]. Neel Jasani, et al. Potent anticancer activity of an orally bioavailable small molecule, ON 013100, and its water soluble derivative, briciclib, a clinical-stage eIF4E-targeted agent. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. |